leflunomide has been researched along with Acute Relapsing Multiple Sclerosis in 2 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Treatment was well tolerated; numbers of adverse events and serious adverse events were similar in all treatment groups." | 2.72 | A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. ( Bar-Or, A; Confavreux, C; Freedman, MS; Li, D; O'Connor, PW; Paty, DW; Rice, GP; Scheyer, R; Stewart, JA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Millar, JA | 1 |
| O'Connor, PW | 1 |
| Li, D | 1 |
| Freedman, MS | 1 |
| Bar-Or, A | 1 |
| Rice, GP | 1 |
| Confavreux, C | 1 |
| Paty, DW | 1 |
| Stewart, JA | 1 |
| Scheyer, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses[NCT01487096] | Phase 2 | 179 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for leflunomide and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
Topics: Adult; Double-Blind Method; Female; Headache; Humans; Immunologic Factors; Isoxazoles; Leflunomide; | 2006 |
1 other study available for leflunomide and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
The cost of teriflunomide in the treatment of relapsing-remitting multiple sclerosis.
Topics: Australia; Cost-Benefit Analysis; Crotonates; Drug Approval; Drug Costs; Financing, Government; Huma | 2019 |